KYLYS was granted an Innosuisse project to develop HA Pearls product towards novel therapeutic application. This project is in collaboration with the University of Geneva.
Read More
KYLYS is pleased to announce that its main patent application filed under the Patent Cooperation Treaty (PCT) convention recently entered the national phases. This is an important step toward protecting KYLYS’s invention in multiple countries worldwide.
Read More
We are very proud to have been selected by the BioInnovation Day 2018 organization to present our project HA Pearls. The 8th edition of BioInnovation Day took place on 15 November 2018 at Geneva’s Life Sciences Hub Campus Biotech, providing an opportunity for researchers, scientist-entrepreneurs and early-stage start-up ventures to pitch their projects to an audience of peers, investors, and industry representatives....
Read More
Proud to announce that our startup KYLYS won the 2nd prize in the Global Healthcare Innovation Academy (GHIA) in Hong-Kong for its new approach to treat osteoarthritis!
Read More
KYLYS is assigned exclusive worldwide rights by University of Geneva on an innovative technology based on hyaluronic acid (HA). HA, a naturally occurring biocompatible molecule found throughout the body that is a vital component of healthy joint and tissue...
Read More
We have presented our technology to a prestigious international meeting: the 44th Annual Meeting & Exposition of the Controlled Release Society in Boston, Massachusetts, United...
Read More